You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 科倫藥業升5% 股價有望挑戰歷史高位 3種藥品獲註冊批准
格隆匯 05-26 11:37
格隆匯5月26日丨科倫藥業(002422.SZ)午間收升4.98%,盤中最高報33.25元,有望衝擊歷史高價,總市值達483億元。近日公司拿下3款新品,氫溴酸替格列汀片為國內首仿,乙磺酸尼達尼布軟膠囊為國產第二家,枸櫞酸託法替布緩釋片為國產第四家。另外,子公司創新藥物SKB264(TROP2-ADC)於2023年ASCO官網公佈研究結果摘要,最常見的≥3級的治療相關不良事件(≥5%)為中性粒細胞計數降低、貧血、白細胞計數降低、口腔黏膜炎、皮疹和淋巴細胞計數降低。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account